- Analysis of the mutational landscape in hematological malignancies, by Next Generation Sequencing.
- Comparison of different evolving tumor stages: pre-malignant stages, diagnosis, refractoriness, relapse, transformation and/or leukemic phases and cell line.
- Clonal heterogeneity: evaluation of different subclones among the main tumor to discover their clinical and prognostic implications. Identification of subclones by MFC and NGS among different hematological malignancies at different evolving stages (diagnosis, complete remission relapse, refractoriness). To define the presence of subclones, their characteristics and their potential implications in the behavior and outcome of the disease.
- Biological studies to investigate new prognostic factors or response predictors.
Such Taboada, EsperanzaLeading Researcher